Trial reportThe Journal of clinical endocrinology and metabolism2018
The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials.
Trial report in The Journal of clinical endocrinology and metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.
- Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE).Journal of endocrinological investigation · 2022Guideline
- Metabolic Effects of Testosterone Added to Intensive Lifestyle Intervention in Older Men With Obesity and Hypogonadism.The Journal of clinical endocrinology and metabolism · 2025Trial
- Baseline Testosterone Predicts Body Composition and Metabolic Response to Testosterone Therapy.Frontiers in endocrinology · 2022Trial
- Biomarkers and Noncalcified Coronary Artery Plaque Progression in Older Men Treated With Testosterone.The Journal of clinical endocrinology and metabolism · 2020Trial
- Changes in cardiometabolic risk factors in transmasculine individuals over 10 years of Gender-Affirming Hormone Therapy.Journal of endocrinological investigation · 2026Article
- Circulating Markers of Cardiovascular Health in Hypogonadism Before and After Testosterone Therapy: Molecular Aspects and Formulation Comparison.International journal of molecular sciences · 2026Review
- Discordance Between Online Information and Male Hypogonadism Clinical Guidelines: A Global Multilingual Content Analysis.The Journal of clinical endocrinology and metabolism · 2026Article
- Associations between erectile dysfunction, low testosterone, and cardiometabolic risk: an age stratified, propensity-matched cohort study.International journal of impotence research · 2026Article
- Metabolism and Type 2 Diabetes Across Life Stages in Klinefelter Syndrome: A Population-Based Cohort Study.The Journal of clinical endocrinology and metabolism · 2026Article
- Role of Vitamin B₆ in Testosterone Synthesis.The world journal of men's health · 2026Review
- Higher Circulating Testosterone Linked to Higher CAD Risk in Men: Mendelian Randomization and Survival Analyses.The Journal of clinical endocrinology and metabolism · 2026Article
- Endogenous Testosterone, Testosterone Treatment, and Cardiovascular Health Outcomes in Men.The Journal of clinical endocrinology and metabolism · 2026Review
- Testosterone and Cardiovascular Health: Physiology, Pharmacokinetics and Clinical Implications.Cardiology and cardiovascular medicine · 2026Article
- Metabolic Messengers: testosterone.Nature metabolism · 2026Review
- Male Hypogonadism: The Korean Society of Men's Health and Aging Position Statement.The world journal of men's health · 2025Review
- Role of Lipoic Acid in Testosterone Production in Males.The world journal of men's health · 2025Review
- [Testosterone-"Fuel" for old men?]Innere Medizin (Heidelberg, Germany) · 2025Review
- Evaluating the impact of testosterone replacement therapy on carotid atherosclerosis: a systematic review and meta-analysis.Future science OA · 2024Review
- Metabolic Features of Assigned Female at Birth Transgender People on Gender-Affirming Hormone Therapy: A Meta-analysis.Transgender health · 2024Review
- Replacement with sex steroids in hypopituitary men and women: implications for gender differences in morbidities and mortality.Reviews in endocrine & metabolic disorders · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
22 authors at 15 institutions in 1 country.
Funding
Abstract
Context: Studies of the possible cardiovascular risk of testosterone treatment are inconclusive. Objective: To determine the effect of testosterone treatment on cardiovascular biomarkers in older men with low testosterone. Design: Double-blind, placebo-controlled trial. Setting: Twelve academic medical centers in the United States. Participants: In all, 788 men ≥65 years old with an average of two serum testosterone levels <275 ng/dL who were enrolled in The Testosterone Trials. Intervention: Testosterone gel, the dose adjusted to maintain the testosterone level in the normal range for young men, or placebo gel for 12 months. Main Outcome Measures: Serum markers of cardiovascular risk, including lipids and markers of glucose metabolism, fibrinolysis, inflammation, and myocardial damage. Results: Compared with placebo, testosterone treatment significantly decreased total cholesterol (adjusted mean difference, -6.1 mg/dL; P < 0.001), high-density lipoprotein cholesterol (adjusted mean difference, -2.0 mg/dL; P < 0.001), and low-density lipoprotein cholesterol (adjusted mean difference, -2.3 mg/dL; P = 0.051) from baseline to month 12. Testosterone also slightly but significantly decreased fasting insulin (adjusted mean difference, -1.7 µIU/mL; P = 0.02) and homeostatic model assessment‒insulin resistance (adjusted mean difference, -0.6; P = 0.03). Testosterone did not change triglycerides, d-dimer, C-reactive protein, interleukin 6, troponin, glucose, or hemoglobin A1c levels more than placebo. Conclusions and Relevance: Testosterone treatment of 1 year in older men with low testosterone was associated with small reductions in cholesterol and insulin but not with other glucose markers, markers of inflammation or fibrinolysis, or troponin. The clinical importance of these findings is unclear and requires a larger trial of clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.